Toi M - Search Results

1

Update results of FEC followed by docetaxel neoadjuvant trials for primary breast cancer.

Ohnoa S, Toi M, Kuroi K, Nakamura S, Iwata H, Kusama M, Masuda N, Yamazaki K, Hisamatsu K, Sato Y, Takatsuka Y, Shin E, Kaise H, Kurozumi M, Tsuda H, Akiyama F. Ohnoa S, et al. Among authors: toi m. Biomed Pharmacother. 2005 Oct;59 Suppl 2:S323-4. doi: 10.1016/s0753-3322(05)80063-0. Biomed Pharmacother. 2005. PMID: 16507401

2

Prognostic significance of co-expression of c-erbB-2 oncoprotein and epidermal growth factor receptor in breast cancer patients.

Osaki A, Toi M, Yamada H, Kawami H, Kuroi K, Toge T. Osaki A, et al. Among authors: toi m. Am J Surg. 1992 Oct;164(4):323-6. doi: 10.1016/s0002-9610(05)80897-9. Am J Surg. 1992. PMID: 1357997

3

[Prognostic significance of expression of c-ERBB-2 oncoprotein in breast cancer patients].

Osaki A, Toi M, Yamada H, Kawami H, Kuroi K, Toge T. Osaki A, et al. Among authors: toi m. Gan To Kagaku Ryoho. 1991 Jun;18(7):1181-5. Gan To Kagaku Ryoho. 1991. PMID: 1675844 Japanese.

4

[Effects of high-dose medroxyprogesterone acetate in advanced breast cancer, with special reference to prior endocrine therapy and hormone receptors].

Nomura Y, Tashiro H, Hisamatsu K, Toi M. Nomura Y, et al. Among authors: toi m. Gan To Kagaku Ryoho. 1988 Mar;15(3):513-8. Gan To Kagaku Ryoho. 1988. PMID: 2964811 Japanese.

5

Primary squamous cell carcinoma of the breast after cured Hodgkin's disease.

Kuroi K, Osaki A, Yamada H, Toi M, Toge T, Takimoto Y, Kuramoto A, Arihiro K, Inai K. Kuroi K, et al. Among authors: toi m. Surg Today. 1993;23(1):81-4. doi: 10.1007/BF00309006. Surg Today. 1993. PMID: 8461611

6

[The feasibility of CEF (cyclophosphamide, epirubicin, 5-FU) regimen in the adjuvant setting of primary breast cancer].

Honda S, Toi M, Shimizu S, Hayashi K, Tominaga T. Honda S, et al. Among authors: toi m. Gan To Kagaku Ryoho. 1997 Apr;24(6):679-83. Gan To Kagaku Ryoho. 1997. PMID: 9126304 Clinical Trial. Japanese.

7

[Docetaxel as a single agent in cases of advanced/recurrent breast cancer previously treated with anthracycline].

Nagai S, Toi M, Kuroi K, Hayashi K, Tominaga T. Nagai S, et al. Among authors: toi m. Gan To Kagaku Ryoho. 1999 Nov;26(13):2037-42. Gan To Kagaku Ryoho. 1999. PMID: 10584568 Clinical Trial. Japanese.

8

Tissue factor expression in breast cancer tissues: its correlation with prognosis and plasma concentration.

Ueno T, Toi M, Koike M, Nakamura S, Tominaga T. Ueno T, et al. Among authors: toi m. Br J Cancer. 2000 Jul;83(2):164-70. doi: 10.1054/bjoc.2000.1272. Br J Cancer. 2000. PMID: 10901365 Free PMC article.

9

[Antiangiogenesis therapy and hormone therapy--their resemblance and applications of prognostic and predictive factors].

Toi M, Matsumoto G, Bando H, Kuroi K. Toi M, et al. Gan To Kagaku Ryoho. 2000 Jul;27(8):1212-6. Gan To Kagaku Ryoho. 2000. PMID: 10945019 Japanese.

10

Significance of macrophage chemoattractant protein-1 in macrophage recruitment, angiogenesis, and survival in human breast cancer.

Ueno T, Toi M, Saji H, Muta M, Bando H, Kuroi K, Koike M, Inadera H, Matsushima K. Ueno T, et al. Among authors: toi m. Clin Cancer Res. 2000 Aug;6(8):3282-9. Clin Cancer Res. 2000. PMID: 10955814

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

785 results

Search Page

Filters